485 related articles for article (PubMed ID: 27653507)
41. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
[TBL] [Abstract][Full Text] [Related]
42. Low-dose rituximab as an adjuvant therapy in pemphigus.
Gupta J; Raval RC; Shah AN; Solanki RB; Patel DD; Shah KB; Badheka AD; Shah KB; Aggarwal NK; Ravishankar V
Indian J Dermatol Venereol Leprol; 2017; 83(3):317-325. PubMed ID: 28366912
[TBL] [Abstract][Full Text] [Related]
43. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission.
Russo I; De Siena FP; Saponeri A; Alaibac M
Medicine (Baltimore); 2017 Nov; 96(46):e8801. PubMed ID: 29145342
[TBL] [Abstract][Full Text] [Related]
45. Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris.
Daneshpazhooh M; Kamyab K; Kalantari MS; Balighi K; Naraghi ZS; Shamohammadi S; Mortazavizadeh SM; Ramezani A; Chams-Davatchi C
Clin Exp Dermatol; 2014 Jan; 39(1):41-7. PubMed ID: 23782219
[TBL] [Abstract][Full Text] [Related]
46. Maintenance treatment of pemphigus with rituximab in real life: A single-center study of 50 patients.
Louchez A; El Aarbaoui T; Weill A; Gaudin O; Jelti L; Belmondo T; Wolkenstein P; Ingen-Housz-Oro S
Ann Dermatol Venereol; 2024 Jun; 151(2):103264. PubMed ID: 38537431
[TBL] [Abstract][Full Text] [Related]
47. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
Londhe PJ; Kalyanpad Y; Khopkar US
Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
[TBL] [Abstract][Full Text] [Related]
48. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study.
Sharma VK; Bhari N; Gupta S; Sahni K; Khanna N; Ramam M; Sethuraman G
Indian J Dermatol Venereol Leprol; 2016; 82(4):389-94. PubMed ID: 27279296
[TBL] [Abstract][Full Text] [Related]
49. Resolution of a case of pediatric pemphigus vulgaris treated with rituximab.
Didona D; Paolino G; Donati M; Caposeina D; Calvieri S; Didona B
Acta Dermatovenerol Croat; 2014; 22(4):288-90. PubMed ID: 25580789
[TBL] [Abstract][Full Text] [Related]
50. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
[TBL] [Abstract][Full Text] [Related]
51. Assessment of the Effects of Rituximab Monotherapy on Different Subsets of Circulating T-Regulatory Cells and Clinical Disease Severity in Severe Pemphigus Vulgaris.
Bhattacharjee R; De D; Handa S; Minz RW; Saikia B; Joshi N
Dermatology; 2016; 232(5):572-577. PubMed ID: 27576321
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial.
Balighi K; Daneshpazhooh M; Khezri S; Mahdavi-nia M; Hajiseyed-javadi M; Chams-Davatchi C
Int J Dermatol; 2013 Jul; 52(7):862-7. PubMed ID: 23789604
[TBL] [Abstract][Full Text] [Related]
53. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months.
Balighi K; Daneshpazhooh M; Akbari Z; Tavakolpour S; Azimi P; Azizpour A
J Dermatolog Treat; 2019 Jun; 30(4):346-349. PubMed ID: 30081690
[No Abstract] [Full Text] [Related]
54. Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study.
Miše J; Jukić IL; Marinović B
Front Immunol; 2022; 13():884931. PubMed ID: 35592312
[TBL] [Abstract][Full Text] [Related]
55. Clinical resolution of pemphigus vulgaris on rituximab.
Cusick E; Silverstein D
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469734
[TBL] [Abstract][Full Text] [Related]
56. Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs.
El-Zawahry B; Bassiouny D; Hegazy R; Gawdat H; Shalaby S; Khorshied M; Saleh MA
Arch Dermatol Res; 2017 Sep; 309(7):551-556. PubMed ID: 28631092
[TBL] [Abstract][Full Text] [Related]
57. [Transition from pemphigus vulgaris to pemphigus foliaceus: a case report].
Lévy-Sitbon C; Reguiaï Z; Durlach A; Goeldel AL; Grange F; Bernard P
Ann Dermatol Venereol; 2013 Dec; 140(12):788-92. PubMed ID: 24315225
[TBL] [Abstract][Full Text] [Related]
58. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients.
Matsukura S; Knowles SR; Walsh S; Shear NH
Arch Dermatol; 2012 Jun; 148(6):734-9. PubMed ID: 22351790
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
[No Abstract] [Full Text] [Related]
60. [Use of rituximab in maintenance treatment of pemphigus: A retrospective series].
Barroil M; Girard C; Lerisson M; Negroni V; Bertrand AS; Pallure V; Bessis D; Guillot B; Dereure O
Ann Dermatol Venereol; 2020 Mar; 147(3):173-178. PubMed ID: 31955970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
